J.ophthalmol.(Ukraine).2021;4:3-8.

Fulltext Pdf 


http://doi.org/10.31288/oftalmolzh2021438

Received: 04 March 2021; Published on-line: 16 August 2021


Сhanges in bacterial keratitis grade 2 in patients with diabetes mellitus

O.V. Zavoloka 1, P.A. Bezditko 1, M.A. Karliychuk 2

1 Kharkiv National Medical University; Kharkiv  (Ukraine)

2 Bukovinian State Medical University; Chernivtsi (Ukraine)

E-mail: Olesya_zavoloka@yahoo.com

TO CITE THIS ARTICLE: Zavoloka OV, Besditko PA, Karliychuk MA.   Сhanges in bacterial keratitis grade 2 in patients with diabetes mellitus. J.ophthalmol.(Ukraine). 2021;4:3-8. http://doi.org/10.31288/oftalmolzh2021438 


Background: The pathological changes in the immune system and inflammatory response in diabetes mellitus (DM) result in impaired wound healing and the chronicity of the immune response.

Purpose: To determine the features of the longitudinal changes in bacterial keratitis grade 2 in patients with type 1 DM.

Material and Methods: We retrospectively reviewed the outcomes of treatment of 19 patients (19 eyes; main group) with both bacterial keratitis grade 2 and type 1 DM and 15 patients (15 eyes; control group) with bacterial keratitis grade 2 only. All patients received topical antibiotic, ofloxacin. In addition, they received topical antiseptics, antioxidants, repairing agents, hyaluronic acid-based artificial tears, and mydriatics and systemic anti-inflammatory agents. Observations were performed within 24 days after initiation of treatment. Patients had a routine eye examination, bacteriological studies, fluorescein dye test, anterior eye OCT and non-contact corneal esthesiometry.

Results: Compared to the controls, patients of the main group showed increased corneal sensitivity within the study period, increased corneal infiltrate depth and corneal edema depth beginning from day 3, and increased severity of pericorneal injection and corneal ulcer depth beginning from day 7 (р < 0.05). In addition, corneal infiltrate resolved in all patients of the main group four days later and corneal edema, seven days later than in controls (р < 0.05). Most patients of the main group had a more severe outcome than did controls. Particularly, on day 24, an ulcer defect was still present in 33.3% of patients of the main group, with corneal haze, nubecula corneae and macula corneae seen in 44.4% and 22.2%, respectively, of patients of this group, versus 93.3% and 6.7%, respectively, for controls (р < 0.05).

Conclusion: The features of the longitudinal changes in bacterial keratitis grade 2 in patients with DM cause prolongation of the course and worsening of outcomes of therapeutic treatment of bacterial keratitis grade 2.

Keywords: diabetes mellitus, bacterial keratitis, severity of bacterial keratitis, longitudinal changes in bacterial keratitis

 

References

1.Wang B, Yang S, Zhai H, Zhang Y, Cui C, Wang J, Xie L. A comparative study of risk factors for corneal infection in diabetic and non-diabetic patients. Int J Ophthalmol. 2018;11(1):43–7.

2.Peleg AY, Weerarathna T, McCarthy JS, Davis TM. Common infections in diabetes: pathogenesis, management and relationship to glycaemic control. Diabetes Metab Res Rev. 2007;23(1):3-13. 

Crossref   PubMed

3.Vital MC, Belloso M, Prager TC, Lanier JD. Classifying the severity of corneal ulcers by using the "1, 2, 3" rule. Cornea. 2007;26(1):16-20. 

Crossref    PubMed

4.Sitnik GV. [Current approaches to the treatment of corneal ulcers].  Meditsinskii Zhurnal. 2007;4:100-14. Russian.

5.Dyck PJ, Dyck PJB: Diabetic polyneuropathy: section III. In: Diabetic Neuropathy. 2nd ed. Dyck PJ, Thomas PK, Eds. Philadelph-ia: W.B. Saunders. 1999; p. 255–78. 

6.Zavoloka OV, Bezditko PA, Lukhanin OO. Efficacy of a novel non-contact corneal esthesiometer in assessing the neurotrophic status of the cornea in type I diabetic patients with bacterial keratitis. J Ophthalmol (Ukraine).  2019;6:29-33. 

Crossref      

7.Tsai S, Clemente-Casares X, Revelo XS, Winer S, Winer DA. Are obesity-related insulin resistance and type 2 diabetes autoim-mune diseases? Diabetes. 2015;64(6):1886-97. 

Crossref   PubMed

8.Gregor MF, Hotamisligil GS. Inflammatory mechanisms in obesity. Annu Rev Immunol. 2011;29:415-45. 

Crossref   PubMed

9.Esser N, Legrand-Poels S, Piette J, Scheen AJ, Paquot N. Inflammation as a link between obesity, metabolic syndrome and type 2 diabetes. Diabetes Res Clin Pract. 2014;105(2):141-50.

Crossref  PubMed

 

Conflict of Interest Statement:

The authors declare no conflict of interest which could influence their opinions on the subject or the materials presented in the manuscript.